This project presents one application direction of the IARIP research architecture. The presented model is currently in the research and pilot validation phase. The timelines below outline the expected validation and development steps of the IARIP research architecture across different application domains. Following research validation, IARIP aims to initiate real-world projects together with industry and market partners based on the successfully validated models.

Development of resonant bioactive formulations to support inflammatory and allergic balance

Project Overview

The objective of this project is to develop a pilot line of therapeutic nutraceutical products that support the body’s natural balance without suppression, using bio-based, gentle, and evidence-informed interventions.

Nutraceuticals—dietary supplements and functional bioactive products—represent a fast, low-regulatory-risk entry point into the health industry. This project integrates plant-based bioactive research, bioinformatics-driven selection, and AI-supported formulation to create safe, high-quality products with clear functional positioning.

The focus is not pharmaceutical drug development, but the creation of reliable, supportive bioactive formulations that:

• – help maintain balanced immune function,
• – support the modulation of inflammatory and allergic processes,
• – contribute to long-term quality of life and resilience.

Pilot Scope (0–24 months)

The pilot phase concentrates on a narrow, clearly defined product set to ensure rapid validation and market readiness.

Pilot objectives:

• – development of 1–2 targeted nutraceutical formulations,
• – rimary focus areas:
  – allergic responses,
  – low-grade chronic inflammation,
  – immune overreactivity and sensitivity,
• – use of safe, plant-derived active ingredients,
• – literature-based and laboratory-supported validation.

Products will be positioned without therapeutic or medical claims, emphasizing supportive, preventive, and wellbeing-enhancing functions.

Technological and Development Approach

The project is structured around three integrated development layers:

1. Active Compound Research and Selection

• – identification of plant-based and natural bioactive compounds,
• – literature and database-driven effect profiling,
• – analysis of immunomodulatory and anti-inflammatory mechanisms.

2. AI-Supported Formulation Design

• – evaluation of synergistic interactions between active compounds,
• – optimization of dosage, absorption, and bioavailability parameters,
• – preliminary modeling of tolerability and safety profiles.

3. Pilot Manufacturing and Validation

• – small-batch production in controlled environments,
• – quality assurance and stability testing,
• – structured collection of non-clinical user feedback.

Expected Pilot Outcomes

The project targets concrete, market-ready deliverables:

• – 1–2 validated nutraceutical prototypes,
• – documented formulation and development methodology,
• – safety- and quality-focused composition framework,
• – product packages suitable for institutional or market testing,
• – a foundation for future personalization or expanded product lines.

The pilot phase represents developmental and market validation, not clinical trials.

Why This Project Is Pilot-Ready and Strategically Strong

• – rapid development cycle (6–12 months),
• – low regulatory and compliance risk,
• – compatibility with existing manufacturing and distribution models,
• – clear relevance for health, wellness, and preventive-care markets.

This project can deliver early, tangible results, while simultaneously establishing a robust knowledge base for more advanced health-technology initiatives.

Alignment with the AVA Development Framework

Within this project, AVA operates as a supportive intelligence layer, contributing to:

• – identification of bioactive patterns and synergistic interactions,
• – optimization of formulation decisions,
• – structured analysis of feedback and performance indicators.

The Therapeutic Nutraceuticals pilot product line thus functions not as an isolated product effort, but as a scalable first step toward a broader, intelligent health-technology ecosystem.